Uncategorized
Retinal atrophy raises concern about long-term anti-VEGF treatment, overdosing
LONDON – Anti-VEGF currently remains the best option for preserving vision in AMD patients, but might as a side effect, accelerate atrophy, according to one specialist. Long-term results of anti-VEGF therapy in various countries show stabilization of vision and positive response in most patients, with an overall 50% reduction of AMD-related legal blindness since the introduction of anti-VEGFs.